Thomas Riga - Spectrum Pharmaceuticals CEO Pres

CEO

Mr. Thomas J. Riga is Chief Operating Officer, Chief Commercial Officer, Executive Vice President of the Company since 2017.
Age 48
Tenure 9 years
Phone617 586 3900
Webhttps://www.sppirx.com
Riga has served as our Chief Operating Officer since December 2017, as Executive Vice President since May 2017 and as our Chief Commercial Officer since August 2014. From June 2017 to December 2017, he served as our Head of Business Development. From August 2014 to June 2017, he served as our Senior Vice President and from July 2013 to August 2014, he served as our Vice President, Corporationrationrationrate Accounts. During his tenure as Chief Commercial Officer, he has led multiple product launches in the oncology market, delivering innovative cancer care. He has consistently inspired crossfunctional teams to deliver superior performance to create value for Spectrum and restructured the commercial organization to advance our competitive advantage.

Spectrum Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.3821) % which means that it has lost $0.3821 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6502) %, meaning that it created substantial loss on money invested by shareholders. Spectrum Pharmaceuticals' management efficiency ratios could be used to measure how well Spectrum Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Spectrum Pharmaceuticals currently holds 29.43 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Spectrum Pharmaceuticals has a current ratio of 1.75, which is within standard range for the sector. Note, when we think about Spectrum Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 2 records

CEO Age

Evert SchimmelpenninkLENZ Therapeutics
53
Neil McFarlaneZevra Therapeutics
52
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts. Spectrum Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 163 people. Spectrum Pharmaceuticals (SPPI) is traded on NASDAQ Exchange in USA and employs 86 people.

Management Performance

Spectrum Pharmaceuticals Leadership Team

Elected by the shareholders, the Spectrum Pharmaceuticals' board of directors comprises two types of representatives: Spectrum Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spectrum. The board's role is to monitor Spectrum Pharmaceuticals' management team and ensure that shareholders' interests are well served. Spectrum Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spectrum Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
MD MBA, VP Devel
Michael Grabow, Exec Officer
Bimal Shah, VP Devel
Nora Brennan, Ex Officer
Thomas Riga, CEO Pres
LLM JD, Chief VP
MD FRCPC, Ex Officer

Spectrum Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spectrum Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Other Consideration for investing in Spectrum Stock

If you are still planning to invest in Spectrum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spectrum Pharmaceuticals' history and understand the potential risks before investing.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Global Correlations
Find global opportunities by holding instruments from different markets
Commodity Directory
Find actively traded commodities issued by global exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments